TiGenix CEO Confident Of European Green Light For Lead Asset
TiGenix CEO Eduardo Bravo outlines group's commercialization plans for CPF candidate Cx601 in Europe and the US.
You may also be interested in...
Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.
Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.